title: Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.
abstract: OBJECTIVE
  To update 5-year results of a previously published study on special 7-days-a-week fractionation continuous accelerated irradiation (CAIR) for head-and-neck cancer patients.
  
  
  METHODS
  One hundred patients with squamous cell carcinoma of head and neck in Stage T(2-4)N(0-1)M(0) were randomized between two definitive radiation treatments: accelerated fractionation 7 days a week including weekends (CAIR) and conventional 5 days a week (control). Hence the overall treatment time was 2 weeks shorter in CAIR.
  
  
  RESULTS
  Five-year local tumor control was 75% in the CAIR group and 33% in the control arm (p < 0.00004). Tumor-cure benefit corresponded with significant improvement in disease-free survival and overall survival rates. Confluent mucositis was the main acute toxicity, with the incidence significantly higher in CAIR patients than in control (respectively, 94% vs. 53%). When 2.0-Gy fractions were used, radiation necrosis developed in 5 patients (22%) in the CAIR group as a consequential late effect (CLE), but when fraction size was reduced to 1.8 Gy no more CLE occurred. Actuarial 5-year morbidity-free survival rate was similar for both treatments.
  
  
  CONCLUSIONS
  Selected head-and-neck cancer patients could be treated very effectively with 7-days-a-week radiation schedule with no compromise of total dose and with slight 10% reduction of fraction dose (2 Gy-1.8 Gy), which article gives 1 week reduction of overall treatment time compared with standard 70 Gy in 35 fractions over 47-49 days. Although this report is based on the relatively small group of patients, its results have encouraged us to use CAIR fractionation in a standard radiation treatment for moderately advanced head-and-neck cancer patients.
authors.affiliation: Department of Radiation Oncology, Center of Oncology-Maria Sklodowska-Curie Memorial Institute, Gliwice, Poland. skladowski@io.gliwice.pl
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Skladowski
authors.forename: Boguslaw
authors.initials: B
authors.lastname: Maciejewski
authors.forename: Maria
authors.initials: M
authors.lastname: Golen
authors.forename: Rafal
authors.initials: R
authors.lastname: Tarnawski
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Slosarek
authors.forename: Rafal
authors.initials: R
authors.lastname: Suwinski
authors.forename: Mariusz
authors.initials: M
authors.lastname: Sygula
authors.forename: Andrzej
authors.initials: A
authors.lastname: Wygoda
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy* / Q000556:secondary; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D016016:Proportional Hazards Models; D011832:Radiation Injuries / Q000150:complications; D016879:Salvage Therapy; D013280:Stomatitis / Q000209:etiology; D013997:Time Factors